Key Drivers
- Strong liquidity
- Large cash burn
- Below book value
AIAI Summary
AbCellera's deliberate pivot from platform services to an internally‑led, manufacturing‑backed biotech makes the stock a binary, catalyst‑driven bet—positive mid‑2026 ABCL635 Phase II data or a high‑quality non‑dilutive funding/partner deal could materially re‑rate shares, while sustained high R&D/capex burn and any CMC delays would likely force dilutive financing and sharply compress valuation.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Large cash burn
- •Below book value
ABCL has strong liquidity and trades below tangible book value but faces substantial operating and free-cash-flow losses from heavy R&D and capex, creating a material cash-burn risk despite low leverage.
Price Behavior
Key Price Behavior Insights:
- •Mild uptrend
- •Early‑March resistance
- •Support cluster
ABCL shows a mild short-term uptrend—close at $3.49 sits ~3% above its last-month mean after an 18.6% runup from $2.94 to $3.82 and a recent ~8.6% pullback, with support near $3.03–$3.19 (and $2.94) and resistance at $3.82.
18.6% climb from $2.94 to $3.82 followed by ~8.6% pullback to $3.49
Sentiment & News
Key News Insights:
- •Pipeline focus
- •Q4 beat
- •ABCL635 Phase II
AbCellera is pivoting from platform services to a pipeline-driven biotech after investing roughly $1B in its platform, reporting a Q4 beat and advancing ABCL635 toward a near-term Phase II catalyst while analysts stay cautious with a consensus Hold.
If ABCL635 delivers positive Phase II data the stock could be re-rated higher, but near-term upside is constrained by prevailing analyst caution and Hold ratings
Similar Companies in Healthcare
Other companies in the same sector with AI ratings